Generation of anti-p53 cytotoxic T lymphocytes from human peripheral blood using autologous dendritic cells. NLM AIDSLINE Important note: Information in this article was accurate in 1999. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Generation of anti-p53 cytotoxic T lymphocytes from human peripheral blood using autologous dendritic cells.

Clin Cancer Res. 1999 Jun;5(6):1281-8. Unique Identifier : AIDSLINE MED/99316772
Chikamatsu K; Nakano K; Storkus WJ; Appella E; Lotze MT; Whiteside TL; DeLeo AB; University of Pittsburgh Cancer Institute, Pennsylvania 15213,; USA.

Abstract: CTLs recognizing the HLA-A2.1-restricted, wild-type sequence p53 epitopes p53(149-157) and p53(264-272) were generated from CD8-enriched populations of nonadherent peripheral blood lymphocytes (PBLs) obtained from healthy donors. The PBLs were restimulated in vitro with peptide-pulsed granulocyte macrophage colony-stimulating factor- and interleukin (IL)-4-induced autologous dendritic cells in the presence of IL-6 and IL-12 and subsequently cultivated with IL-1alpha, IL-2, IL-4, IL-6, and IL-7. Bulk anti-p53(264-272) CTL populations were generated from PBLs obtained from two of five donors. Both CTL populations were cytotoxic against peptide-pulsed HLA-A2+ target cells, but not against untreated target cells. A CD8+ anti-p53 CTL clone designated p264#2 was isolated from one of the bulk populations. It was found to have an intermediate affinity of approximately 10(-9) M for the epitope and to mediate cytotoxicity against several human tumor cell lines, including the squamous cell carcinoma of the head and neck cell line SCC-9, which is known to present the wild-type sequence p53(264-272) epitope. In addition, CTLs reactive against p53(149-157)-pulsed targets as well as a HLA-A2+ tumor cell line were cloned from a bulk population of antitumor CTLs obtained from one of the five normal PBLs restimulated with this epitope. The results indicate that CTLs recognizing wild-type sequence epitopes can be generated from precursors present in PBLs obtained from some normal individuals using autologous dendritic cells as antigen-presenting cells and suggest that vaccine strategies targeting these epitopes can lead to antitumor CTL generation, thereby emphasizing the therapeutic potential of p53-based cancer vaccines.
Keywords: JOURNAL ARTICLE Antigens, CD/METABOLISM Cell Separation Cells, Cultured Clone Cells/IMMUNOLOGY Cytotoxicity Tests, Immunologic CD8-Positive T-Lymphocytes/IMMUNOLOGY Dendritic Cells/*IMMUNOLOGY Epitopes/IMMUNOLOGY Human HLA-A2 Antigen/IMMUNOLOGY Interleukins/METABOLISM Lymphocyte Subsets/IMMUNOLOGY Peptide Fragments/IMMUNOLOGY Protein p53/GENETICS/*IMMUNOLOGY Support, U.S. Gov't, P.H.S. T-Lymphocytes, Cytotoxic/*IMMUNOLOGY/METABOLISM Tumor Cells, CulturedKWDjournalarticleantigens,cd/metabolismcellseparationcells,culturedclonecells/immunologycytotoxicitytests,immunologiccd8-positivet-lymphocytes/immunologydendriticcells/KWDimmunologyepitopes/immunologyhumanhla-a2antigen/immunologyinterleukins/metabolismlymphocytesubsets/immunologypeptidefragments/immunologyproteinp53/genetics/KWDimmunologysupport,uKWDsKWDgov't,pKWDhKWDsKWDt-lymphocytes,cytotoxic/KWDimmunology/metabolismtumorcells,cultured
991230
A99C0996

Copyright © 1999 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1999. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1999. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .